Treatment outcomes after 6 months among all HIV-1 infected patients in Sweden on Eviplera
Catharina Maijgren Steffensson1, 3, Göran Skoglund1, Veronica Svedhem Johansson2, 3
Affiliates: 1Gilead Sciences Sweden, Solna, Sweden, 2Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, 3Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
Eviplera is a single tablet regimen (STR ) containing tenofovir disoproxil fumarate, emtricitabine and rilpivirine to be taken once daily in adults infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the NNRTI class or tenofovir or emtricitabine, and with a plasma viral load ≤ 100 000 HIV -1 RNA copies/ml.
368 patients were started on Eviplera in Sweden prior to the 30th of November 2013. 352 of them have >6 months follow up and are included in this report. The data is collected retrospectively from the National Quality Register InfCareHIV, which includes all patients diagnosed with HIV-1 in Sweden. No patient was lost to follow-up.
Among the 352 patients, 99 patients were antiretroviral naïve at initiation and 253 were treatment experienced. Of the 253 treatment experienced patients, 27 switched to Eviplera because of treatment failure and 226 switched due to side effects. The majority of the patients who switched to Eviplera because of side effects were previously on treatment with an efavirenz- based regimen. In treatment naïve patients, 95/99 initiated treatment with Eviplera with a baseline viral load of < 100 000 HIV-1 RNA copies/ml. All 99 patients in the treatment naive group achieved virological suppression (< 150 copies/mL) at 6 months. Of the treatment experienced patients who switched from their previous regimen due to side effects, 221/226 achieved virological suppression at 6 months. Of the patients who switched to Eviplera due to treatment failure, 21 out of 27 had <150-1 HIV RNA copies/ml at 6 months.
Eviplera was associated with high rates of virologic suppression in both treatment naïve and experienced patients.